1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

FDA Seeks Input On Inactive Ingredients Database

US Agency Plans To Prioritize Maximum Daily Exposure Information

 
• By Dave Wallace

Industry input is being sought by the FDA on its inactive ingredient database, as the US agency considers how to prioritize the addition of maximum daily exposure limits as well as mulling the removal of specific dosage form information.

Grunge red inactive word with star icon round rubber seal stamp on white background
The FDA is seeking feedback on changes to its inactive ingredient database • Source: Thanee Hengpattanapong / Alamy Stock Vector

Input is being solicited by the US Food and Drug Administration on how best to prioritize the addition of maximum daily exposure information to its inactive ingredient database, as well as potentially modifying the IID structure to eliminate dosage form information.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Biosimilars & Generics

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

Biosimilars Industry Celebrates EMA’s Plan to Reduce Clinical Trials

 
• By Dave Wallace

The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.